UAE Clinical Nutrition for Chronic Kidney Diseases Market Report 2023 to 2030

UAE Clinical Nutrition for Chronic Kidney Diseases Market Analysis

$ 3999

UAE Clinical Nutrition for Chronic Kidney Diseases Market was valued at $7.80 Mn in 2023 and is predicted to grow at a CAGR of 7.03% from 2023 to 2030, to $12.60 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, growing awareness and diagnosis, advancements in medical research, and the aging population. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.

ID: IN10AEPH568 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Sarita Yadav

Buy Now

UAE Clinical Nutrition for Chronic Kidney Diseases Market Executive Summary

UAE Clinical Nutrition for Chronic Kidney Diseases Market was valued at $7.80 Mn in 2023 and is predicted to grow at a CAGR of 7.03% from 2023 to 2030, to $12.60 Mn by 2030.

Chronic kidney disease (CKD) is a gradual loss of kidney function over at least three months, often progressing silently due to the absence of early symptoms. The main causes include diabetes and high blood pressure, though family history and other conditions also contribute. As CKD advances through stages, it may necessitate dialysis or a kidney transplant and is associated with increased risks of heart disease, stroke, and bone issues. Management focuses on slowing disease progression, symptom management, and preventing complications through dietary changes, medications, and blood pressure control. Key dietary adjustments include moderating protein intake, managing fluid levels, controlling electrolytes like sodium, potassium, and phosphorus, and ensuring sufficient calorie intake to avoid malnutrition. Early detection and screening are crucial for those at risk.

The prevalence of CKD stages 3-5 among UAE nationals is around 4.6% in males and 2.8% in females. The incidence of end-stage renal disease (ESRD) was 135 per Mn population, with 260 ESRD patients per Mn on dialysis, totaling approximately 2,500 dialysis patients. The market therefore is driven by significant factors like the rising prevalence of CKD, growing awareness and diagnosis, advancements in medical research, and the aging population. However, the high cost of treatment, limited reimbursement, and scarcity of qualified dietitians restrict the growth and potential of the market.

Prominent players in this field are Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.

UAE Clinical Nutrition for Chronic Kidney Diseases Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Rising Prevalence of CKD: The increasing incidence of chronic kidney disease (CKD) in the UAE, driven by high rates of diabetes, hypertension, and obesity, fuels the demand for specialized clinical nutrition products designed for CKD management.

Aging Population: The UAE's aging population, prone to CKD, drives demand for specialized clinical nutrition products. Estimates show a projected increase to nearly 2 Mn people aged 60+ by 2050 (19.7% of the population), a more than six-fold rise from 2020 figures, highlighting the need for targeted healthcare solutions.

Growing Awareness and Diagnosis: Improved awareness and early diagnosis of CKD among healthcare professionals and the general population are leading to earlier interventions and a greater need for specialized nutritional products to manage the disease effectively.

Advancements in Medical Research: Ongoing research into the role of nutrition in managing CKD is resulting in the development of innovative nutritional products tailored to the specific needs of CKD patients, driving market growth.

Market Restraints

High Cost of Treatment: In the UAE, the high costs of CKD medications, specialized nutritional products, and dietitian consultations can be prohibitive for many patients. This financial burden significantly limits access to comprehensive CKD care, affecting the overall quality of treatment and health outcomes.

Limited Reimbursement: In the UAE, reimbursement for CKD-specific clinical nutrition products is limited. Both public and private health insurance frequently exclude these specialized products, posing a significant barrier for patients and potentially hindering market growth.

Scarcity of Qualified Dietitians: There is a shortage of dietitians in the UAE with expertise in CKD nutrition, which restricts patients' access to specialized nutritional guidance and tailored dietary management plans.

Regulatory Landscape and Reimbursement Scenario

In UAE, the regulatory framework for CKD-specific clinical nutrition involves several key authorities. The Ministry of Health and Prevention (MOHAP) is the primary federal body responsible for regulating food products, including those for special medical purposes like CKD management. MOHAP sets standards for labeling, safety, and quality, and issues guidelines for the import, registration, and marketing of these products. Additionally, the Department of Health Abu Dhabi (DoHA) and Dubai Health Authority (DHA) may implement their own regulations within their jurisdictions. The UAE uses a positive list system, allowing only pre-approved food products to be imported, registered, and sold.

The reimbursement scenario for CKD clinical nutrition in the UAE is currently evolving. The national health insurance program, Thiqa, may cover some consultations with dietitians and specific medically necessary nutritional products, although coverage details vary based on individual insurance plans. Private health insurance plans also offer varying degrees of coverage for CKD nutritional interventions, with some covering dietitian consultations and specific nutritional products, while others may have limited coverage or require prior authorization. The specifics of coverage can vary significantly depending on the patient's insurance policy and provider.

Competitive Landscape

Key Players

Here are some of the major key players in the UAE Clinical Nutrition for Chronic Kidney Diseases Market

Abbott Nutrition
Pfizer Inc.
Bayer AG
Nestlé Health Science
Otsuka Pharmaceutical
Mead Johnson & Company, LLC
Danone S.A.
Victus, Inc.
B. Braun Melsungen AG
Fresenius Kabi AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Clinical Nutrition for Chronic Kidney Diseases Market Segmentation

Product

Oral Nutrition
Parenteral Nutrition
Enteral Feeding Formulas

Stages

Adult
Paediatric

Sales Channel

Online
Retail
Institutional Sales

End-User

Hospitals
Homecare
Specialty Clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.